Skip to content

Effect of Saffron in Coronary Artery Diseases

Effect of Supplementation with Crocetin (Saffron carotenoids) on Antioxidant Indices, Inflammatory index and Serum Leptin Concentration in Patients with Coronary Artery Diseases: A Double-Blind Randomized Clinical Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220902055853N2
Enrollment
50
Registered
2023-05-18
Start date
2023-06-09
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Diseases. Atherosclerotic heart disease of native coronary artery

Interventions

Intervention 1: Intervention group: supplementation of Crocetin (10 mg dry crocetin powder, 1 capsules of 125 mg daily) one hour before lunch for period of 8 weeks. Intervention 2: Control group: Dail

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 65 Years

Inclusion criteria

Inclusion criteria: Coronary artery occlusion disease Willingness to participate in the study Age range of 40 to 65 years BMI 25-35

Exclusion criteria

Exclusion criteria: Having heart attack lactation or pregnancy Having any infectious disease Chang the usual medications Irregular consumption of interventional capsules Taking food supplement, vitamin and mineral for at least in the last 3 months Participate in another trial simultaneously Having an Allergic reaction to interventional herb

Design outcomes

Primary

MeasureTime frame
Hs-CRP. Timepoint: At the beginning and end of study. Method of measurement: Serum sample.

Secondary

MeasureTime frame
Superoxide dismutase (SOD). Timepoint: At the beginning and end of study. Method of measurement: Serum sample.;Malondialdehyde (MDA). Timepoint: At the beginning and end of study. Method of measurement: Serum sample.;Catalase(CAT). Timepoint: At the beginning and end of study. Method of measurement: Serum sample.;Leptin. Timepoint: At the beginning and end of study. Method of measurement: Serum sample.;Plasma atherogenic index. Timepoint: At the beginning and end of study. Method of measurement: Calculated by log (TG/HDL-C).;Systolic and Diastolic Blood Pressure. Timepoint: At the beginning and end of study. Method of measurement: Mercury sphygmomanometer.;Physical activity. Timepoint: At the beginning and end of study. Method of measurement: International Physical ActivityQuestionnaire.;Dietary intake (Energy, Carbohydrate, Fat, Protein). Timepoint: At the beginning and end of study. Method of measurement: Using Nutritionist IV software.;Weight. Timepoint: At the beginning and end of study. Method of measurement: Weight measured with minimal clothing and no shoes with an accuracy of 0.1 Using a kilogram scale.;Body mass index. Timepoint: At the beginning and end of study. Method of measurement: Weight in kilograms divided by height in meters squared.kg/m2.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFaezeh Moeini Badi

Ahvaz University of Medical Sciences

moeinibadifaezeh@gmail.com+98 61 3336 2414

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026